Creating a treatment to prevent or delay Alzheimer's disease using a growth hormone blocker
Development of a Growth Hormone Receptor antagonist for the delay or prevention of ADRD
This study is looking at a new way to help prevent or slow down Alzheimer's disease by targeting a hormone that affects brain health, inspired by older people who seem to resist dementia, and it hopes to find out if lowering this hormone can help improve memory and protect against cognitive decline.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Molecular Technologies Laboratories LLC NIH-funded |
| Lab location | 1 site (Columbus, United States) |
| Project ID | NIH-11062348 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment that targets the growth hormone signaling pathway to prevent or delay Alzheimer's disease and related dementias. It is based on findings from centenarians who show resilience to dementia and carry genetic variants that lower growth hormone activity. The study will explore how reducing growth hormone levels can protect against cognitive decline and improve memory in both animal models and potentially in humans. By understanding the mechanisms behind this protection, the research aims to identify innovative therapeutic strategies for Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research include older adults, particularly those with a family history of Alzheimer's disease or related dementias.
Not a fit: Patients who are not at risk for Alzheimer's disease or those with advanced stages of dementia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that significantly delays or prevents the onset of Alzheimer's disease in at-risk populations.
How similar studies have performed: Previous studies have shown promising results in using similar approaches to target growth hormone signaling for cognitive protection, indicating potential for success in this novel application.
Where this research is happening
Columbus, United States
- Molecular Technologies Laboratories LLC — Columbus, United States (Active)
Researchers
- Principal investigator: Brody, Richard S — Molecular Technologies Laboratories LLC
- Study coordinator: Brody, Richard S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.